EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of vitamin D on COVID-19 risk and hospitalisation in the UK biobank

Maria J Monroy-Iglesias iD, Rathesh Thavarajah, Kerri Beckmann, Debra H Josephs, Sheeba Irshad, Sophia N Karagiannis, Mieke Van Hemelrijck, Aida Santaolalla

PLOS One · 2025

DOI: 10.1371/journal.pone.0328232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Maria J Monroy-Iglesias und 7 weiteren Autor:innen. Beteiligte Einrichtung: Transforming Outcomes through Research (TOUR), Centre for Cancer, Society, and Public Health, School of Cancer and Pharmaceutical Sciences, King's Co…. Hauptthemen laut MEDLINE: COVID-19, Hospitalization, Vitamin D, Vitamin D Deficiency. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vitamin D (VitD) plays an important role in immune modulation. VitD deficiency is associated with increased susceptibility to acute respiratory syndrome as observed in COVID-19. We evaluated potential associations between serum VitD levels and risk of COVID-19 infection and hospitalisation, within the overall and cancer populations.

Methods

We performed a nested case-control study within the UK biobank cohort, among all individuals with at least one serum VitD level measurement at baseline (2006−2010) and a COVID-19 polymerase chain reaction (PCR) results recorded, and individuals with previous cancer diagnosis. Binary multivariable logistic regression was performed to assess associations between VitD levels and risk of COVID-19 infection (positive PCR), and hospitalisation (COVID-19-positive PCR in hospital), and stratified by ethnicity.

Results

Of 151,543 participants, 21,396 tested positive for COVID-19. Of 24,400 individuals with cancer, 2,608 tested positive. In the total cohort, VitD insufficiency (Adjusted Odds Ratio (aOR) 0.97, 95% Confidence Interval (CI) 0.94–1.00) and deficiency (aOR 0.95, 95%CI 0.90–0.99) were associated with slightly lower odds of COVID-19 infection. In contrast, both VitD insufficiency (aOR 1.19, 95%CI 1.08–1.31) and deficiency (aOR 1.36, 95%CI 1.19–1.56) were associated with higher odds of COVID-19 hospitalisation. Among Asian (aOR 1.50; 95%CI 1.08–2.07) and Black (aOR 1.57; 95%CI 1.14–2.16) participants, VitD deficiency was associated with higher odds of COVID-19 infection. Among White participants, VitD insufficiency was associated with slightly lower odds of COVID-19 infection (aOR 0.97; 95%CI 0.86–0.95), while both VitD insufficiency (aOR 1.19; 95%CI 1.08–1.32) and deficiency (aOR 1.44; 95%CI 1.25–1.66) were associated with increased odds of hospitalisation. In the cancer population, vitamin D deficiency was associated with higher odds of infection only among Black participants (aOR 3.50; 95%CI 1.22–10.01); no other associations were observed.

Conclusions

Low VitD levels were associated with an increased risk of COVID-19 hospitalisation but showed only a weak association with infection risk. Black and Asian populations had higher infection risk associated with VitD deficiency, but this did not translate to increased hospitalisation. In contrast, White populations with low VitD levels exhibited a higher risk of hospitalisation. There was no evidence of an interaction between VitD levels and ethnicity affecting infection or hospitalisation risk. In the cancer cohort, no significant associations were observed for COVID-19 infection or hospitalisation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HospitalizationVitamin DVitamin D DeficiencyHumansMaleFemaleUnited KingdomMiddle AgedCase-Control StudiesAgedBiological Specimen BanksSARS-CoV-2Risk FactorsNeoplasmsAdultUK Biobank

Substanzen

Vitamin D

Autor:innen und Institutionen

  • Transforming Outcomes through Research (TOUR), Centre for Cancer, Society, and Public Health, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • Cancer Epidemiology and Population Health Research Group, University of South Australia, Adelaide, Australia.
  • Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • St. John's Institute of Dermatology School of Basic & Medical Biosciences, & KHP Centre for Translational Medicine, King's College London, London, United Kingdom.

ORCID-Profile: Maria J Monroy-Iglesias

Zitieren

APA

Monroy-Iglesias, M. J., Thavarajah, R., Beckmann, K., Josephs, D. H., Irshad, S., Karagiannis, S. N., Van Hemelrijck, M., & Santaolalla, A. (2025). Effects of vitamin D on COVID-19 risk and hospitalisation in the UK biobank. PLOS One. https://doi.org/10.1371/journal.pone.0328232

Vancouver

Monroy-Iglesias MJ, Thavarajah R, Beckmann K, Josephs DH, Irshad S, Karagiannis SN, et al. Effects of vitamin D on COVID-19 risk and hospitalisation in the UK biobank. PLOS One. 2025. doi:10.1371/journal.pone.0328232

BibTeX
@article{MonroyIglesias2025,
  author = {Monroy-Iglesias, Maria J and Thavarajah, Rathesh and Beckmann, Kerri and Josephs, Debra H and Irshad, Sheeba and Karagiannis, Sophia N and Van Hemelrijck, Mieke and Santaolalla, Aida},
  title = {Effects of vitamin D on COVID-19 risk and hospitalisation in the UK biobank},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0328232}
}
Kostenlos starten →